Results 51 to 60 of about 6,410,935 (343)
Genetic mechanisms of resistance to protease inhibitors and entry inhibitors [PDF]
HIV Clinical Trials, 2002 Resistance to protease inhibitors (PIs) often appears as a result of changes at codons within the protease gene, which differ from one drug to another. When PIs are boosted with low doses of ritonavir, multiple mutations at the protease are required to reduce significantly the antiviral activity of these compounds.
Vincent, Soriano, Carmen, de Mendoza
openaire +2 more sources
Emerging Microbes and Infections, 2018 Sodium taurocholate cotransporting polypeptide (NTCP) is a functional receptor for hepatitis B virus (HBV) entry. However, little is known regarding whether NTCP is involved in regulating the postentry steps of the HBV life cycle.
Kai-Tao Zhao +14 more
semanticscholar +1 more source
Trilobatin as an HIV‐1 entry inhibitor targeting the HIV‐1 Gp41 envelope
FEBS Letters, 2018 HIV‐1 transmembrane protein gp41 plays a crucial role by forming a stable six‐helix bundle during HIV entry. Due to highly conserved sequence of gp41, the development of an effective and safe small‐molecule compound targeting gp41 is a good choice ...
Shuwen Yin +8 more
semanticscholar +1 more source
Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor
Viruses, 2018 The recent 2014–2016 West African Ebola virus epidemic underscores the need for the development of novel anti-Ebola therapeutics, due to the high mortality rates of Ebola virus infections and the lack of FDA-approved vaccine or therapy that is available ...
Q. Cui +8 more
semanticscholar +1 more source
Molecular Pharmaceutics, 2018 Peptides often suffer from short in vivo half-lives due to proteolysis and renal clearance that limit their therapeutic potential in many indications, necessitating pharmacokinetic (PK) enhancement.
Joseph S. Redman +7 more
semanticscholar +1 more source
Viruses, 2023 The utility of human neuroblastoma cell lines as in vitro model to study neuro-invasiveness and neuro-virulence of SARS-CoV-2 has been demonstrated by our laboratory and others.
Margaux Mignolet +10 more
doaj +1 more source
Selection of Human Cytomegalovirus Mutants with Resistance against PDGFRα-Derived Entry Inhibitors
Viruses, 2021 The human cytomegalovirus (HCMV) infects fibroblasts via an interaction of its envelope glycoprotein gO with the cellular platelet-derived growth factor receptor alpha (PDGFRα), and soluble derivatives of this receptor can inhibit viral entry.
Kerstin Laib Sampaio +4 more
doaj +1 more source
Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin +17 more
wiley +1 more source
Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures. [PDF]
PLoS ONE, 2013 Efforts to treat HCV patients are focused on developing antiviral combinations that lead to the eradication of infection. Thus, it is important to identify optimal combinations from the various viral inhibitor classes.
Caroline O Bush +3 more
doaj +1 more source
Frontiers in Microbiology, 2022 LCB1 is a 56-mer miniprotein computationally designed to target the spike (S) receptor-binding motif of SARS-CoV-2 with potent in vitro and in vivo inhibitory activities (Cao et al., 2020; Case et al., 2021).
Tong Wu +5 more
doaj +1 more source